{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:12:11Z","timestamp":1780495931618,"version":"3.54.1"},"reference-count":44,"publisher":"Portland Press Ltd.","issue":"5","license":[{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"crossref","award":["IAA"],"award-info":[{"award-number":["IAA"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000268","name":"Biotechnology and Biological Sciences Research Council","doi-asserted-by":"crossref","award":["HEIF"],"award-info":[{"award-number":["HEIF"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Antimicrobial resistance (AMR) poses a significant global health threat, as it contributes to prolonged illness, higher mortality rates and increased healthcare costs. As traditional antibiotics become less effective, treatments such as bacteriophage therapy offer potential solutions. The question remains, however, on how to set research priorities in the face of a growing number of antibiotic-resistant pathogens, some common and\/or dangerous. One standard way of making decisions about which research to prioritise is by using the disability-adjusted life year metric to estimate the current global impact of a disease or condition, combined with considerations of social justice although decisions made at a national level by governments, especially in low income countries with forecasting potential over future needs may look very different. Another approach is based on the needs of researchers and regulators given what we know about the technology itself. The biological characteristics of bacteriophage therapies set challenges to a universal and standardised prioritisation method. A proof of principle is still arguably needed. With a preliminary discussion of the scope and complexity of AMR and AMR therapeutics, we propose some implications of regulatory frameworks aiming to integrate bacteriophage therapy into mainstream medical practice while gathering scientific data on safety and efficacy, enhancing the collective action needed to combat AMR.<\/jats:p>","DOI":"10.1042\/ebc20240013","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T14:01:55Z","timestamp":1730296915000},"page":"679-686","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Considerations for prioritising clinical research using bacteriophage"],"prefix":"10.1042","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1723-5012","authenticated-orcid":false,"given":"Sarah\u00a0J.L.","family":"Edwards","sequence":"additional","affiliation":[{"name":"1STEaPP, University College London, 255309, Gower Street, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiran","family":"Tao","sequence":"additional","affiliation":[{"name":"2STS, University College London, 265201, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodas","family":"Elias","sequence":"additional","affiliation":[{"name":"3STS, University College London, 265202, London, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schooley","sequence":"additional","affiliation":[{"name":"4Division of Infectious Diseases, University of California San Diego, 265203, San Diego, California, U.S.A."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"288","published-online":{"date-parts":[[2024,12,17]]},"reference":[{"key":"2024121707561561600_B1","first-page":"629","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","journal-title":"Lancet North Am. Ed."},{"key":"2024121707561561600_B2","doi-asserted-by":"crossref","DOI":"10.1596\/26707","volume-title":"Drug-Resistant Infections: A Threat to Our Economic Future","author":"World Bank","year":"2017"},{"key":"2024121707561561600_B3","article-title":"Global research agenda for antimicrobial resistance in human health (Policy brief)","author":"World Health Organization","year":"2023"},{"key":"2024121707561561600_B4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/1745-6215-15-287","article-title":"A systematic review of factors affecting children's right to health in cluster randomized trials in Kenya","volume":"15","author":"Oduwo","year":"2014","journal-title":"Trials"},{"key":"2024121707561561600_B5","doi-asserted-by":"publisher","first-page":"e0262823","DOI":"10.1371\/journal.pone.0262823","article-title":"An anchor in troubled times: Trust in science before and within the COVID-19 pandemic","volume":"17","author":"Bromme","year":"2022","journal-title":"PloS ONE"},{"key":"2024121707561561600_B6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.4161\/viru.25991","article-title":"A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens","volume":"5","author":"Wittebole","year":"2014","journal-title":"Virulence"},{"key":"2024121707561561600_B7","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1093\/jac\/dkw083","article-title":"Bacteriophage therapy: a regulatory perspective","volume":"71","author":"Pelfrene","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"2024121707561561600_B8","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"2024121707561561600_B9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/v15041020","article-title":"Current clinical landscape and global potential of bacteriophage therapy","volume":"15","author":"Hitchcock","year":"2023","journal-title":"Viruses"},{"key":"2024121707561561600_B10","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/antibiotics11101340","article-title":"The safety and efficacy of phage therapy: a systematic review of clinical and safety trials","volume":"11","author":"Stacey","year":"2022","journal-title":"Antibiotics"},{"key":"2024121707561561600_B11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1093\/cid\/ciy947","article-title":"A systematic and critical review of bacteriophage therapy against multidrug-resistant ESKAPE organisms in humans","volume":"69","author":"El Haddad","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"2024121707561561600_B12","volume-title":"Bacteriophage Therapy in Tonsillitis","author":"Tashkent Pediatric Medical Institute (Uzbekistan)","year":"2020"},{"key":"2024121707561561600_B13","volume-title":"Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis (No. WHO\/EMP\/IAU\/2017.12)","author":"World Health Organization","year":"2017"},{"key":"2024121707561561600_B14","volume-title":"Phage Safety Cohort Study (PHA-SA-CO)","author":"Hospices Civils de Lyon (France)","year":"2023"},{"key":"2024121707561561600_B15","volume-title":"Phage Safety Retrospective Cohort Study (PHASACO-retro)","author":"Hospices Civils de Lyon (France)","year":"2022"},{"key":"2024121707561561600_B16","volume-title":"Bacteriophage Therapy for Methicillin-Sensitive Staphylococcus Aureus Prosthetic Joint Infection (PHAGE-2024-01)","author":"University of Calgary (Canada)","year":"2024"},{"key":"2024121707561561600_B17","volume-title":"Phage Therapy in Prosthetic Joint Infection Due to Staphylococcus Aureus Treated With DAIR. (PhagoDAIRI)","author":"Pherecydes Pharma (France)","year":"2023"},{"key":"2024121707561561600_B18","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","volume":"81","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"2024121707561561600_B19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12961-018-0391-0","article-title":"An analysis of research priority-setting at the World Health Organization\u2014how mapping to a standard template allows for comparison between research priority-setting approaches","volume":"16","author":"Terry","year":"2018","journal-title":"Health Res. Policy Systems"},{"key":"2024121707561561600_B20","volume-title":"Health research prioritization at WHO: an overview of methodology and high level analysis of WHO led health research priority setting exercises (draft)","author":"Viergever","year":"2010"},{"key":"2024121707561561600_B21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1478-4505-8-36","article-title":"A checklist for health research priority setting: nine common themes of good practice","volume":"8","author":"Viergever","year":"2010","journal-title":"Health Res. Policy Systems"},{"key":"2024121707561561600_B22","volume-title":"Methods and data sources for global burden of disease estimates 2000-2019 (Global Health Estimates Technical Paper, No. WHO\/DDI\/DNA\/GHE\/2020.3)","author":"Department of Data and Analytics","year":"2020"},{"key":"2024121707561561600_B23","volume-title":"A systematic approach for undertaking a research priority-setting exercise: guidance for WHO staff (No. who-334408)","author":"World Health Organization","year":"2020"},{"key":"2024121707561561600_B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"2024121707561561600_B25","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.cmi.2021.01.004","article-title":"Methodological quality of studies evaluating the burden of drug-resistant infections in humans due to the WHO Global Antimicrobial Resistance Surveillance System target bacteria","volume":"27","author":"Pezzani","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"2024121707561561600_B26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/phe\/phaa030","article-title":"The Devils in the DALY: prevailing evaluative assumptions","volume":"13","author":"Solberg","year":"2020","journal-title":"Public Health Ethics"},{"key":"2024121707561561600_B27","first-page":"28","article-title":"The Rise, Critique and Persistence of the DALY in Global Health","volume":"4","author":"Parks","year":"2014","journal-title":"Columbia J. Global Health"},{"key":"2024121707561561600_B28","article-title":"From resistance to resilience: What could the future antibiotic pipeline look like?","author":"International Federation of Pharmaceutical Manufacturers and Associations","year":"2024"},{"key":"2024121707561561600_B29","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1377\/hlthaff.2021.00688","article-title":"Estimating The Appropriate Size Of Global Pull Incentives For Antibacterial Medicines: Study examines global antibacterial pull incentives","volume":"40","author":"Outterson","year":"2021","journal-title":"Health Aff."},{"key":"2024121707561561600_B30","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/antibiotics12061012","article-title":"Bacteriophages in Infectious Diseases and Beyond-A Narrative Review","volume":"12","author":"Ioannou","year":"2023","journal-title":"Antibiotics"},{"key":"2024121707561561600_B31","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-41986-2_38","article-title":"Clinical trials of bacteriophage therapeutics","volume-title":"Bacteriophages","author":"McCallin","year":"2021"},{"key":"2024121707561561600_B32","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/antibiotics9110827","article-title":"Phage Therapy: Towards a Successful Clinical Trial","volume":"9","author":"G\u00f3rski","year":"2020","journal-title":"Antibiotics"},{"key":"2024121707561561600_B33","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3390\/v15030721","article-title":"The future of clinical phage therapy in the united kingdom","volume":"15","author":"Jones","year":"2023","journal-title":"Viruses"},{"key":"2024121707561561600_B34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","article-title":"Principles of early drug discovery","volume":"162","author":"Hughes","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"2024121707561561600_B35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/0020731420979824","article-title":"Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19","volume":"51","author":"Lexchin","year":"2021","journal-title":"Int. J. Health Service"},{"key":"2024121707561561600_B36","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.ymthe.2018.04.007","article-title":"Registry Contributions to Strengthen Cell and Gene Therapeutic Evidence","volume":"26","author":"Abou-El-Enein","year":"2018","journal-title":"Mol. Ther."},{"key":"2024121707561561600_B37","volume-title":"Reflection paper on establishing efficacy based on single-arm trials submitted as pivotal evidence in a marketing authorisation (Reference No. EMA\/CHMP\/564424\/2021)","author":"Committee for Medicinal Products for Human Use","year":"2023"},{"key":"2024121707561561600_B38","doi-asserted-by":"publisher","first-page":"107506","DOI":"10.1016\/j.cct.2024.107506","article-title":"Single-arm phase 3 designs: An oxymoron?","volume":"141","author":"Hussein","year":"2024","journal-title":"Contemporary Clinical Trials"},{"key":"2024121707561561600_B39","doi-asserted-by":"publisher","first-page":"e075000","DOI":"10.1136\/bmj-2023-075000","article-title":"Considering tomorrow's patients in today's drug approvals","volume":"381","author":"Lynch","year":"2023","journal-title":"BMJ"},{"key":"2024121707561561600_B40","doi-asserted-by":"publisher","first-page":"e065401","DOI":"10.1136\/bmjopen-2022-065401","article-title":"Phage Australia Clinical Network. Standardised treatment and monitoring protocol to assess safety and tolerability of bacteriophage therapy for adult and paediatric patients (STAMP study): protocol for an open-label, single-arm trial","volume":"9","author":"Khatami","year":"2022","journal-title":"BMJ Open"},{"key":"2024121707561561600_B41","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.clinthera.2022.01.012","article-title":"Real-World Evidence for Regulatory Decision-Making: Guidance From Around the World","volume":"44","author":"Burns","year":"2022","journal-title":"Clin. Ther."},{"key":"2024121707561561600_B42","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat. Microbiol."},{"key":"2024121707561561600_B43","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1002\/sim.9663","article-title":"The Personalised Randomized Controlled Trial: Evaluation of a new trial design","volume":"42","author":"Lee","year":"2023","journal-title":"Stat. Med."},{"key":"2024121707561561600_B44","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/15265161.2020.1795516","article-title":"The Case for Methodological Pluralism in Medical Science","volume":"20","author":"Edwards","year":"2020","journal-title":"Am. J. Bioeth."}],"container-title":["Essays in Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/68\/5\/679\/965018\/ebc-2024-0013c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article-pdf\/68\/5\/679\/965018\/ebc-2024-0013c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,17]],"date-time":"2024-12-17T07:56:32Z","timestamp":1734422192000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/essaysbiochem\/article\/68\/5\/679\/235199\/Considerations-for-prioritising-clinical-research"}},"subtitle":[],"editor":[{"given":"Joanne M","family":"Santini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,12,17]]},"published-print":{"date-parts":[[2024,12,17]]}},"URL":"https:\/\/doi.org\/10.1042\/ebc20240013","relation":{},"ISSN":["0071-1365","1744-1358"],"issn-type":[{"value":"0071-1365","type":"print"},{"value":"1744-1358","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,12]]}}}